New Zealand markets open in 4 hours 56 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
125.60-0.19 (-0.15%)
As of 11:04AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close125.79
Bid125.53 x 800
Ask125.56 x 900
Day's range125.35 - 126.58
52-week range91.51 - 127.79
Avg. volume1,275,249
Market cap282.742B
Beta (5Y monthly)0.34
PE ratio (TTM)38.29
EPS (TTM)3.28
Earnings dateN/A
Forward dividend & yield1.60 (1.26%)
Ex-dividend date12 Aug 2022
1y target est129.29
  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 5 December 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme

  • Zacks

    Beat the Market Like Zacks: Novo Nordisk, Axon, General Mills in Focus

    Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

  • Zacks

    Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

    The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.